| Name | Title | Contact Details |
|---|
Lehigh Valley Technology is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2000, San Antonio-based CaptureRx is a healthcare technology company and leading 340B solution provider that puts people first, touching millions of patient lives through customer obsession and innovative products and services that support relationships among payers, providers, pharmacies and patients. Our solutions manage inventory and financial flow for 340B prescriptions filled at contract pharmacies and perform the eligibility checks required to comply with 340B program requirements. Using a process that`s seamless to the covered entity, pharmacy and patient, our Cumulus platform has processed more than 190 million patient encounters and more than 750 million switch claims. Currently, CaptureRx solutions serve more than 500 hospitals and health centers in 45 states via a robust pharmacy network of more than 3,500 contracted locations of independent, national and regional pharmacies.
Servier Laboratories is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France.
Renaissance Pharmaceuticals is Your Partner for Nasal Sprays and Sterile Solutions. Trusted, Reliable, Contract Development, and Manufacturing.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.